Repros Therapeutics Company Profile (NASDAQ:RPRX)

About Repros Therapeutics

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: RPRX
  • CUSIP: 76028H20
Key Metrics:
  • Previous Close: $2.10
  • 50 Day Moving Average: $2.08
  • 200 Day Moving Average: $1.83
  • 52-Week Range: $24,319,000.00 - $0.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: -0.11
  • Market Cap: $52.53M
  • Outstanding Shares: 24,319,000
  • Beta: -0.37
Profitability:
  • Net Margins: -53,658.53%
  • Return on Equity: -130.80%
  • Return on Assets: -114.15%
Debt:
  • Current Ratio: 5.60%
  • Quick Ratio: 5.60%
Additional Links:
Companies Related to Repros Therapeutics:

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $2.24 (3.47% upside)
Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2016S&P Equity ResearchBoost Price Target$2.12 -> $2.47View Rating Details
2/9/2016Piper Jaffray Cos.Reiterated RatingNeutralView Rating Details
12/4/2015Brean CapitalReiterated RatingHoldView Rating Details
10/30/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
10/30/2015Bank of America Corp.DowngradeNeutral -> UnderperformView Rating Details
7/28/2015LaidlawReiterated RatingBuy$28.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.20)($0.18)ViewN/AView Earnings Details
5/10/2016Q1($0.22)($0.20)ViewN/AView Earnings Details
3/14/2016Q4($0.27)($0.26)ViewN/AView Earnings Details
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
Current Year EPS Consensus Estimate: $-0.7 EPS

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Repros Therapeutics (NASDAQ:RPRX)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 24.14%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
DateHeadline
News IconToday Repros Therapeutics Inc Stock Rises | Kentucky News - Post News (NASDAQ:RPRX)
www.kentuckypostnews.com - September 25 at 2:57 PM
News IconKeen Investors Find News on Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 23 at 6:35 PM
News IconUnder the Microscope, Zeroing in at Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 23 at 6:35 PM
News IconPenny Stock Investors Keen on Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 22 at 11:54 AM
News IconPenny Stock Investors Take an Interest in Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 21 at 11:08 AM
News IconUnder the Microscope: Getting a Closer Look at Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 20 at 12:23 PM
News IconKeen Investors Narrowing Their Focus on Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 15 at 7:12 PM
News IconStock Update, a Closer Look at Repros Therapeutics Inc. (NASDAQ:RPRX) - Duncan Research (NASDAQ:RPRX)
www.duncanindependent.com - September 15 at 7:12 PM
streetinsider.com logoRepros Therapeutics (RPRX) Submits MAA for Enclomiphene to EMA as Secondary Hypogonadism Treatment (NASDAQ:RPRX)
www.streetinsider.com - September 14 at 11:30 AM
investingnews.com logoRepros Submits MAA to the European Medicines Agency for Enclomiphene (NASDAQ:RPRX)
investingnews.com - September 14 at 11:30 AM
News IconRepros Therapeutics Announces Submission Of MAA To The EMA For Enclomiphene In The Treatment Of Secondary Hypogonadism (NASDAQ:RPRX)
www.biospace.com - September 14 at 11:30 AM
finance.yahoo.com logoRepros Seeks EU Approval for Secondary Hypogonadism Drug (NASDAQ:RPRX)
finance.yahoo.com - September 13 at 11:59 AM
smarteranalyst.com logoCompany Update (NASDAQ:RPRX): Repros Therapeutics Inc Announces Submission of MAA to the European ... - Smarter Analyst (NASDAQ:RPRX)
www.smarteranalyst.com - September 12 at 6:44 PM
finance.yahoo.com logoRepros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism (NASDAQ:RPRX)
finance.yahoo.com - September 12 at 11:51 AM
benzinga.com logoRepros Therapeutics Inc. (NASDAQ:RPRX), Tailored Brands ... - Benzinga (NASDAQ:RPRX)
www.benzinga.com - September 10 at 6:20 PM
marketexclusive.com logoHere’s What The Latest Data Could Mean For Repros Therapeutics Inc (NASDAQ:RPRX) (NASDAQ:RPRX)
marketexclusive.com - September 9 at 6:45 PM
News IconNotable Hot Runners: Repros Therapeutics Inc (NASDAQ:RPRX), Las Vegas Sands Corp. (NYSE:LVS), Starwood ... - NYSE Journal (press release) (NASDAQ:RPRX)
stockznews.com - September 9 at 11:51 AM
News IconThe Sell-side Consensus is in on Repros Therapeutics Inc. (NASDAQ:RPRX); Earnings & Target Updates - National Daily Press (NASDAQ:RPRX)
www.nationaldailypress.com - September 9 at 11:51 AM
insidermonkey.com logoHere's What Latest Data Could Mean For Repros Therapeutics Inc (RPRX) - Insider Monkey (blog) (NASDAQ:RPRX)
www.insidermonkey.com - September 9 at 11:51 AM
247wallst.com logoWhy Repros Is Rising (NASDAQ:RPRX)
247wallst.com - September 8 at 6:47 PM
insidermonkey.com logoWhy Twitter, AMD and 2 Other Stocks Are in the Red Today, While Repros is Surging (NASDAQ:RPRX)
www.insidermonkey.com - September 8 at 6:47 PM
News IconHere’s What Latest Data Could Mean For Repros Therapeutics Inc (RPRX) (NASDAQ:RPRX)
feedproxy.google.com - September 8 at 2:28 PM
investors.com logoRepros Therapeutics' menstrual pain drug trial excites shares (NASDAQ:RPRX)
www.proactiveinvestors.com - September 8 at 10:54 AM
finance.yahoo.com logoRepros Therapeutics' (RPRX) Proellex Positive in Phase II (NASDAQ:RPRX)
finance.yahoo.com - September 8 at 10:54 AM
benzinga.com logo6 After-Hours Movers: Clinical Trials, Earnings & Public Offerings (NASDAQ:RPRX)
www.benzinga.com - September 7 at 7:13 PM
publicnow.com logoRepros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis (NASDAQ:RPRX)
www.publicnow.com - September 7 at 7:13 PM
investornewswire.com logoWill Repros Therapeutics Inc. (NASDAQ:RPRX) Hit $2 Price Target? - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - August 22 at 11:47 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:RPRX)
biz.yahoo.com - August 18 at 7:28 PM
finance.yahoo.com logoREPROS THERAPEUTICS INC. Financials (NASDAQ:RPRX)
finance.yahoo.com - August 17 at 7:33 PM
streetinsider.com logoRepros Therapeutics (RPRX) Issues Update on Enclomiphene Study vs. Diet and Exercise in Secondary Hypogonadal Men (NASDAQ:RPRX)
www.streetinsider.com - August 16 at 10:31 AM
zacks.com logoRepros Presents 6-Month Interim Data on Enclomiphene (NASDAQ:RPRX)
www.zacks.com - August 16 at 10:31 AM
4-traders.com logoRepros Therapeutics : Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men (NASDAQ:RPRX)
www.4-traders.com - August 16 at 10:31 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events (NASDAQ:RPRX)
biz.yahoo.com - August 15 at 7:35 PM
finance.yahoo.com logo4:03 pm Repros Therapeutics provides a six month update on results from its ongoing 15 month study of secondary hypogonadal men of diet and exercise in combination with enclomiphene treatment (NASDAQ:RPRX)
finance.yahoo.com - August 15 at 7:35 PM
publicnow.com logoRepros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men (NASDAQ:RPRX)
www.publicnow.com - August 15 at 7:35 PM
globenewswire.com logoRepros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:RPRX)
globenewswire.com - August 11 at 10:29 AM
cnbc.com logoRepros Therapeutics reports 2Q loss (NASDAQ:RPRX)
www.cnbc.com - August 10 at 10:19 AM
biz.yahoo.com logoREPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:RPRX)
biz.yahoo.com - August 9 at 10:27 AM
publicnow.com logoRepros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results (NASDAQ:RPRX)
www.publicnow.com - August 9 at 10:27 AM
finance.yahoo.com logoRepros (RPRX) Q2 Earnings: What's in Store for the Stock? (NASDAQ:RPRX)
finance.yahoo.com - August 4 at 10:22 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 17.78% on July 29 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 30 at 9:59 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 5.88% on July 28 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 29 at 10:13 AM
equities.com logoRepros Therapeutics Inc. (RPRX) Drops 5.08% on July 25 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 27 at 10:15 AM
News IconChecking in on Stock Volatility for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 21 at 7:31 PM
News IconPerformance watch list: Repros Therapeutics Inc. (NASDAQ:RPRX) - News Oracle (NASDAQ:RPRX)
www.newsoracle.com - July 21 at 7:31 PM
News IconStock Bending Down in Today's Session: Repros Therapeutics Inc. (NASDAQ:RPRX) - TGP (NASDAQ:RPRX)
telanaganapress.com - July 20 at 8:04 PM
News IconNews review of 2 biotech stocks: Repros Therapeutics (RPRX), Eleven Biotherapeutics (EBIO) - The Voice Registrar (NASDAQ:RPRX)
voiceregistrar.com - July 20 at 8:04 PM
equities.com logoRepros Therapeutics Inc. (RPRX) Jumps 16.57% on July 19 - Equities.com (NASDAQ:RPRX)
www.equities.com - July 20 at 8:04 PM
investornewswire.com logoStrong Sell Calls For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire (NASDAQ:RPRX)
www.investornewswire.com - July 18 at 12:43 PM
News IconShares Moving Down on the Week: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily (NASDAQ:RPRX)
www.engelwooddaily.com - July 17 at 11:17 AM

Social

Repros Therapeutics (NASDAQ:RPRX) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff